Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized two-period phase 3 study of dasiglucagon in children with congenital hyperinsulinism
MOH_2019-05-13_007131Phase 3Recruiting
- Sponsor
- Zealand Pharma
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of dasiglucagon in congenital hyperinsulinism (HI) (2 arms), sponsored by Zealand Pharma. Started Feb 2019; status: recruiting.
02
Drugs
dasiglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on MOH_2019-05-13_007131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-13_007131.